PDCD1 and inflammatory bowel disease: As immune checkpoint inhibitor (ICI) targeting the PD-1/PD-L1 pathway and CTLA-4 is expanding its indications in various advanced malignancies, the use of ICI in patients previously diagnosed with IBD is also increasing.